Texas is currently home to 4894 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
NCT04008797
Recruiting
The primary objective of this study is to assess the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with other anticancer drug(s), and to determine the optimal dose of E7386 in combination with lenvatinib in endometrial carcinoma (EC) (for EC Dose Optimization Part only).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2025
Locations: Mary Crowley Cancer Research, Dallas, Texas
Conditions: Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms
Register for Updates
89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma
NCT04006522
Recruiting
This is an exploratory clinical trial to assess the potential of 89Zr-DFO-Atezolizumab Positron Emission Tomography/Computed Tomography (PET/CT) scans in patients with locally advanced or metastatic renal cell carcinoma (RCC). This open label, nontherapeutic trial will test the correlation of 89Zr-DFO-Atezolizumab immunoPET/CT with programmed death-ligand 1 (PD-L1) expression and the response to immune checkpoint inhibitor therapy in patients with RCC. There will be two cohorts, one made up of p... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2025
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Renal Cell Carcinoma
Register for Updates
Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy
NCT00991094
Recruiting
This study collects information on the side effects of proton therapy and detailed information on the proton therapy treatment plan itself. This may help researchers develop methods to predict the risk of side effects for future patients and learn the long-term benefit of proton therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Breast Carcinoma, Esophageal Carcinoma, Genitourinary System Carcinoma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Lung Carcinoma, Malignant Central Nervous System Neoplasm, Malignant Digestive System Neoplasm, Malignant Solid Neoplasm
Register for Updates
Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP
NCT07027111
Recruiting
The purpose of the study is to evaluate the safety of NVG-2089 and to evaluate how well patients respond to this investigational treatment. NVG-2089 is a new drug that is being developed for treating patients with CIDP. NVG-2089 is designed to mimic the effects of a protein called IVIg. NVG-2089 is designed to potentially help the immune system by attaching (binding) to certain receptors in the body and activating them, which helps reduce inflammation and supports how the immune system works.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/10/2025
Locations: Nuvig Site, Denton, Texas
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy
Register for Updates
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
NCT07011667
Recruiting
This study will look at how well CagriSema helps people living with obesity to lose weight and maintain the weight loss long-term. The study has 2 parts: The first part is called 'the main study' and the second part is called 'the extension study'. In the main study participants will either get CagriSema (a study medicine) or placebo (a dummy medicine that looks like CagriSema but has no active ingredient). Which treatment participants get is decided by chance. Participants are two times more li... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/10/2025
Locations: Amarillo Med Spec LLP, Amarillo, Texas
Conditions: Obesity
Register for Updates
5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer
NCT06887218
Recruiting
This is a non-inferiority randomized phase II trial investigating the efficacy and safety of 5FU/LV in combination with regorafenib for patients with metastatic colorectal cancer in the third-line setting. Patients will be randomly assigned in a 1:1 ratio between 5FU/LV combined with regorafenib or trifluridine-tipiracil (FTD-TPI) plus bevacizumab. Arm 1 (Treatment Arm) will consist of the 5FU/LV administered to 26 patients as (LV \[400 mg/m² IV over 120 minutes\], followed by 5FU \[400 mg/m²... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/10/2025
Locations: Houston Methodist Neal Cancer Center, Houston, Texas
Conditions: Metastatic Colorectal Cancer (CRC)
Register for Updates
Omnipod® SmartAdjust 2.0 System Compared to the Omnipod® 5 System in Individuals With Type 1 or Type 2 Diabetes
NCT06865989
Recruiting
The goal of this multi-center, randomized, cross-over study is to evaluate the safety and effectiveness of the Omnipod 5 SmartAdjust 2.0 System in individuals with type 1 or type 2 diabetes. Study participants will complete about 5 in-person visits and be expected to treat their diabetes per their usual routine using the system at the lowest available target setting. Each participant will begin the study using either the Omnipod 5 SmartAdjust 2.0 System or the Omnipod 5 System for 4 weeks (Per... Read More
Gender:
ALL
Ages:
Between 2 years and 70 years
Trial Updated:
06/10/2025
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Diabetes Mellitus, Type 1, Type 2
Register for Updates
Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.
NCT06810726
Recruiting
The goal of this investigational study is to evaluate the safety and clinical performance of Tropocells Autologous Platelet-rich Fibrin (PRF) for wound care for both males and females, ages 18-80 years old, with Grade 1 and 2, mild to moderate, neuroischemic diabetic chronic foot ulcers in subjects with Type 1 and Type 2 Diabetes Mellitus. The main question\[s\] it aims to answer \[is/are\]: Measure 1: Wound Closure with Tropocells Autologous PRF System for DFU Measure 2: Safety of Tropocells A... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/10/2025
Locations: WoundCentrics Wound Care & Hyperbarics -Corpus Christi - Shoreline, Corpus Christi, Texas
Conditions: Diabetic Foot Ulcer, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus (T2DM), Neuroischemic Foot Ulcer, Chronic Wound of the Lower Limb (Leg Ulcer or Foot Ulcer), Chronic Wound Care
Register for Updates
Combining Esketamine and Prolonged Exposure Treatment for PTSD (Post Traumatic Stress Disorder)
NCT06795659
Recruiting
This study is being done to see if Prolonged Exposure (PE), a well-researched, very effective individual (one-to-one) behavioral therapy designed to help people to directly deal with traumatic events they have suffered in the past, can be combined with intranasal esketamine (ketamine) for the treatment of posttraumatic stress disorder (PTSD) to enhance treatment benefits. Ketamine nasal spray is a drug approved by the U.S. Food \& Drug Administration (FDA) for treatment resistant depression. Com... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/10/2025
Locations: The University of Texas Health Science Center at San Antonio, San Antonio, Texas
Conditions: Post Traumatic Stress Disorder PTSD
Register for Updates
Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy
NCT06679270
Recruiting
This Phase 3 study is an Open Label Extension of the APG-20 Study To Evaluate the Long-term Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects with Partial Lipodystrophy
Gender:
ALL
Ages:
13 years and above
Trial Updated:
06/10/2025
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Familial Partial Lipodystrophy
Register for Updates
P2a Open Label Study to Evaluate 2-HPβCD in Subjects With Diabetic Kidney Disease
NCT06489340
Recruiting
This is an open label, two to three center study to evaluate the clinical efficacy and safety of 1 dose level of 2-hydroxypropyl-β-cyclodextrin (2-HPβCD) given intravenously in adult patients with type 2 diabetes with diabetic kidney disease (DKD) and proteinuria.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/10/2025
Locations: Clinical Advancement Center, PLLC, San Antonio, Texas
Conditions: Diabetic Kidney Disease
Register for Updates
Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION)
NCT06460844
Recruiting
A Phase 1, open-label, non-randomized, dose-escalation study, where approximately 18 eligible patients with retinitis pigmentosa or choroideremia will be enrolled sequentially in up to 4 dose cohorts of RTx-015. Enrolled patients will receive a single, unilateral intravitreal injection of RTx-015 in the study eye at Visit 3 (Day 0) and be followed for a total of 5 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/10/2025
Locations: Retina Consultants of Texas Research Centers, Bellaire, Texas
Conditions: Retinitis Pigmentosa, Choroideremia
Register for Updates